Kura Oncology, Inc. (KURA) SEC Filings & Earnings Calls

Dependence on KOMZIFTI commercial success; pipeline execution risk.

“Single product revenue; clinical trial enrollment ongoing.”

Commercial execution risk

“We expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution of KOMZIFTI.” · word for word

Dependence on Kyowa Kirin collaboration

“Under the terms of the collaboration and license agreement that we entered into with Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc., or together Kyowa Kirin, in November 2024, or the Kyowa License Agreement, we lead commercial strategy for and are responsible for manufacturing KOMZIFTI in the United States.” · word for word

Need for additional financing

“We will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts.” · word for word

Enhanced severance and change-in-control benefits may increase cash outflow upon executive departure or acquisition.

“Cash lump sum payments of up to 24 months base salary plus 200% target bonus for CEO in change-in-control scenario.”

Dependence on KOMZIFTI for revenue

“We have begun generating product revenue from sales of KOMZIFTI. In the first quarter of 2026 – the first full quarter of commercialization – we achieved $5.8 million in KOMZIFTI net product revenue.” · word for word

Need for additional financing

“We anticipate that we will require significant additional financing in the future to continue to fund our operations as discussed more fully below under the heading 'Liquidity and Capital Resources.'” · word for word

Clinical trial risks for pipeline candidates

“Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations.” · word for word

Competition from other menin inhibitors

“Among private payors, several published policies require patients with relapsed or refractory NPM1-mutated AML to step through KOMZIFTI first before receiving other available menin inhibitors.” · word for word

Cost of product sales expected to increase

“We expect the cost of product sales for KOMZIFTI to increase in relation to product revenues as we deplete these inventories.” · word for word

Net loss increased to $73.3M from $57.4M due to higher R&D and SG&A expenses

“Net loss: $73.3 million, compared to $57.4 million for Q1 2025” · word for word

Dependence on successful clinical trial outcomes for ziftomenib across multiple indications

“Multiple clinical data readouts expected in 2026 across combination regimens and treatment settings” · word for word

Clinical and regulatory risk for pipeline candidates

“The timing of FDA approval of our NDA and subsequent commercial launch were impacted by external regulatory factors, including changes in the FDA review environment following our NDA submission, which contributed to periods of uncertainty in the review process.” · word for word

Dependence on key personnel and ability to retain talent

“Our future performance depends significantly upon the continued service of our key scientific, technical and senior management personnel and our continued ability to attract and retain highly skilled employees.” · word for word

Competition for talent and equity dilution

“Our industry is competitive and future success depends on our ability to attract, retain, and motivate a talented workforce.” · word for word

Commercial execution risk for KOMZIFTI launch

“We are now at a critical stage of execution of our first commercial launch. Our ability to attract and retain highly talented and skilled individuals with extensive experience in the pharmaceutical industry is critical to the success of our launch and the continued progress of our clinical development programs.” · word for word

Clinical trial risk; pipeline dependency on ziftomenib and darlifarnib.

“Multiple 2026 clinical data milestones expected; potential for trial failure.”

Commercialization execution risk

“We have not, as an organization, launched or commercialized a product, and there is no guarantee that we will be able to do so successfully with KOMZIFTI.” · word for word

Reimbursement uncertainty

“The availability and extent of coverage and reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments.” · word for word

Competitive pressure

“KOMZIFTI also competes with revumenib (REVUFORJ®), another FDA-approved menin inhibitor targeting relapsed or refractory NPM1-mutated AML as well as relapsed or refractory KMT2A-rearranged acute leukemia.” · word for word

Drug pricing pressure

“The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS and related agencies.” · word for word

Early launch stage; revenue still small; competition in AML space.

“KOMZIFTI net revenue $2.1M in first 5 weeks; R/R NPM1-m AML market has other treatments.”

Dependence on single product KOMZIFTI; pipeline still in clinical stages.

“KOMZIFTI is the only commercial product; pipeline programs are in Phase 1/2/3.”

Commercialization risk for KOMZIFTI; Kyowa Kirin payment timing risk.

“risks related to Kyowa Kirin’s ability to make the expected milestone payment, including on the anticipated timing; risks associated with the commercialization of KOMZIFTI” · word for word

Competition from approved menin inhibitor

“In the case of ziftomenib, in November 2024, Syndax Pharmaceuticals, Inc., or Syndax, announced the FDA's approval of revumenib (Revuforj®), another menin inhibitor, in relapsed or refractory KMT2A-rearranged acute leukemia in adult and pediatric patients one year and older, and in October 2025, Syndax announced the FDA's approval of their supplemental NDA f” · word for word

Dependence on Kyowa Kirin collaboration

“Our collaboration with Kyowa Kirin is important to our business. If Kyowa Kirin ceases development efforts under the Kyowa License Agreement, or if the Kyowa License Agreement is terminated, we may not receive future milestone payments or royalties under the Kyowa License Agreement and our business could be adversely affected.” · word for word

Clinical trial and regulatory risk

“We are highly dependent on the success of our lead product candidate, ziftomenib, which is still in clinical development, and we cannot give any assurance that ziftomenib or any of our other product candidates will receive regulatory approval, which is necessary before they can be commercialized.” · word for word

FDA approval uncertainty for ziftomenib

“Although we submitted, and the FDA has accepted, our NDA seeking approval for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation, there can be no assurance that the FDA will approve the NDA.” · word for word

Safety risk - differentiation syndrome

“The most common treatment-related serious adverse event observed to date with ziftomenib, occurring in more than 10% of patients, is DS. While no Grade 4/5 treatment-related DS has been observed in patients with NPM1-mutated AML treated with ziftomenib, we note that during its review of the NDA for ziftomenib for the treatment of adult patients with NPM1-mut” · word for word

Clinical-stage company with no approved products; net loss widening and reliance on partnership funding

“Net loss for Q3 2025 was $74.1 million, compared to $54.4 million in Q3 2024; no product revenue”

Clinical trial risk; Phase 3 results uncertain.

“KOMET-017 Phase 3 registrational trials of ziftomenib; trials may fail.” · word for word